In the current study, we analyzed a group of patients suffering from relapsing-remitting MS who received in our center an experimental therapy consisting of CD4+CD25highCD127−FoxP3+ regulatory T cells. This evidence concerns the gene CD4 and relapsing-remitting multiple sclerosis.